Commonwealth of Pennsylvania Public School Empls Retrmt SYS Sells 523 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Posted by Defense World Staff on Aug 18th, 2023

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lessened its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 1.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 48,581 shares of the company’s stock after selling 523 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS owned about 0.11% of Pacira BioSciences worth $1,983,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Dimensional Fund Advisors LP boosted its position in shares of Pacira BioSciences by 8.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 947,369 shares of the company’s stock valued at $36,578,000 after purchasing an additional 70,141 shares in the last quarter. Engineers Gate Manager LP acquired a new stake in Pacira BioSciences during the fourth quarter worth approximately $2,012,000. State of New Jersey Common Pension Fund D grew its stake in Pacira BioSciences by 15.4% during the first quarter. State of New Jersey Common Pension Fund D now owns 54,882 shares of the company’s stock worth $2,240,000 after purchasing an additional 7,306 shares during the period. Federated Hermes Inc. grew its stake in Pacira BioSciences by 332,486.7% during the first quarter. Federated Hermes Inc. now owns 149,664 shares of the company’s stock worth $6,108,000 after purchasing an additional 149,619 shares during the period. Finally, Inspire Investing LLC grew its stake in Pacira BioSciences by 9.8% during the first quarter. Inspire Investing LLC now owns 6,674 shares of the company’s stock worth $272,000 after purchasing an additional 595 shares during the period. Institutional investors own 99.75% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Piper Sandler decreased their target price on Pacira BioSciences from $60.00 to $50.00 and set an “overweight” rating for the company in a research note on Thursday, August 3rd. Royal Bank of Canada decreased their target price on Pacira BioSciences from $70.00 to $68.00 and set an “outperform” rating for the company in a research note on Thursday, August 3rd. TD Cowen raised Pacira BioSciences from a “market perform” rating to an “outperform” rating and set a $50.00 target price for the company in a research note on Thursday, August 3rd. Needham & Company LLC reduced their price objective on Pacira BioSciences from $60.00 to $52.00 and set a “buy” rating for the company in a research note on Thursday, August 3rd. Finally, HC Wainwright reduced their price objective on Pacira BioSciences from $68.00 to $63.00 and set a “buy” rating for the company in a research note on Thursday, August 3rd. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Pacira BioSciences has an average rating of “Moderate Buy” and an average price target of $58.00.

Get Our Latest Analysis on PCRX

Insider Activity

In other news, COO Daryl Gaugler sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, May 31st. The stock was sold at an average price of $39.08, for a total value of $97,700.00. Following the transaction, the chief operating officer now owns 24,591 shares in the company, valued at $961,016.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, COO Daryl Gaugler sold 2,500 shares of Pacira BioSciences stock in a transaction on Wednesday, May 31st. The stock was sold at an average price of $39.08, for a total transaction of $97,700.00. Following the sale, the chief operating officer now directly owns 24,591 shares in the company, valued at $961,016.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark A. Kronenfeld sold 15,000 shares of Pacira BioSciences stock in a transaction on Thursday, June 8th. The stock was sold at an average price of $37.04, for a total value of $555,600.00. Following the sale, the director now owns 17,897 shares in the company, valued at $662,904.88. The disclosure for this sale can be found here. Insiders have sold 42,776 shares of company stock worth $1,618,564 over the last 90 days. 6.60% of the stock is currently owned by corporate insiders.

Pacira BioSciences Stock Performance

PCRX stock opened at $36.53 on Friday. Pacira BioSciences, Inc. has a twelve month low of $34.08 and a twelve month high of $58.74. The company has a debt-to-equity ratio of 0.66, a quick ratio of 3.10 and a current ratio of 3.94. The stock’s 50 day moving average is $38.08 and its 200-day moving average is $40.20.

Pacira BioSciences Company Profile

(Free Report)

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves.